Introduction
============

Colorectal cancer is a common type of digestive cancer worldwide. Its incidence has increased rapidly in recent years and seriously impacts human health. In 2018, over 1.8 million new cases and 881,000 deaths were estimated to have occurred, accounting for about 1 in 10 cancer cases and deaths worldwide ([@ref-6]). Among cancer-related diseases, colorectal cancer ranks third in terms of incidence and second in terms of mortality ([@ref-6]). With changes in people's lifestyles and dietary habits, China has experienced an upward trend in both the incidence and mortality of colorectal cancer in the last decade, which now rank fourth and fifth among cancers, respectively ([@ref-20]). Unlike other cancers, no single risk factor accounts for most cases of colorectal cancer ([@ref-7]). Dietary intake, nutritional status, physical activity and other changes have shown to be associated with pathogenesis and poor outcomes of colorectal cancer ([@ref-25]). Widely epidemiological and observational evidence showed the risk of colorectal cancer is strictly related to lifestyle, especially to diet and physical activity ([@ref-29]). In analytical case-control and cohort studies, risk is directly associated with the consumption of red and processed meat ([@ref-23]).

The most common colorectal cancer is colon adenocarcinoma (COAD), which accounts for 66.1% of the disease ([@ref-15]). Overall COAD survival has not substantially improved over the past few decades ([@ref-19]) and its prognosis remains poor due to the delay in diagnosis, advanced stage of disease, and lack of histology-specific treatment ([@ref-2]). Therefore, identification of novel biomarkers for early diagnosis and development of histology-specific targets is one of the foremost challenges for individual treatment of COAD.

There is a strong and multifaceted connection between cell metabolism and cancer ([@ref-26]). Altered cellular metabolism can meet cancer cell anabolic demands that result from untethered cellular growth and aberrant differentiation. Metabolic reprogramming is widely observed during cancer development to confer cancer cells the ability to survive and proliferate, even under stressful conditions, such as limited nutrients ([@ref-17]). Energy metabolism reprogramming, which fuels fast cell growth and proliferation by adjustments in energy metabolism, is considered an emerging hallmark of cancer ([@ref-12]). Thus, new strategies for treating various malignancies by targeting cancer metabolism are gaining increasing attention.

In the current study, we aimed to identify potential targets involved in COAD metabolism by performing comprehensive transcriptome-wide analysis of COAD gene expression patterns. We systematically analyzed clusters of genes with similar expression patterns using weighted gene co-expression network analysis (WGCNA) and found the MEred module to be highly associated with histological typing. Further analysis of the MEred module identified glycerophosphodiester phosphodiesterase 1 (GDE1) as the most significant gene associated with COAD histological typing prognosis. Thus, GDE1 may serve as a candidate biomarker in COAD metabolism and may be a key gene for histology-specific treatment.

Materials and Methods
=====================

Data collection
---------------

We downloaded 289 COAD tumor samples (transcripts per million, TPM) from The Cancer Genome Atlas (TCGA, [https://portal.gdc.cancer.gov/repository](https://portal.gdc.cancer.gov/repository))) and 41 peritumoral normal tissues of COAD (TPM) from the UCSC Xena website (<https://xena.ucsc.edu/>). The data were analyzed with a unifying pipeline, which used a CutAdapt trimming adapter, STAR for alignment, and RSEM and Kallisto as quantifiers. The COAD clinical data were downloaded from the TCGA database using the 'cgdsr' package ([@ref-22]; [@ref-14]).

Differentially expressed gene (DEG) screening
---------------------------------------------

We downloaded metabolism-associated genes from RECON3, the most comprehensive human metabolic network model which contains 13543 reaction, 4140 metabolites, and 3288 metabolic genes ([@ref-8]), and identified 3,267 genes that corresponded to the TPM data. We removed lowly expressed genes (TPM \<1) from the COAD and normal samples, and thus retained 2,747 genes. We used principal component analysis (PCA). To obtain significantly changed genes in COAD, we used the 'aov' function to analyze the DEGs between the COAD and normal samples. We obtained 2,114 significant DEGs in COAD with a *p* \< 0.01 cutoff.

Co-expression network construction by WGCNA
-------------------------------------------

WGCNA can be used to analyze global gene expression profiling and identify highly co-expressed genes. We installed WGCNA with Bioconductor (<http://bioconductor.org/biocLite.R>) for co-expression analysis of metabolism-related genes in COAD. The soft threshold method was used for correlation analysis of the expression profiles. We used average linkage hierarchical clustering to group transcripts based on topological overlap dissimilarity in network connection strengths. We set the minimum gene number of each module to 30 and cutHeight parameter to 0.25 to merge similar modules.

Identification of significant histological type modules
-------------------------------------------------------

To incorporate external information into the co-expression network, WGCNA uses gene significance measures GS (minus log of a *p*-value). A gene significance measure indicates (the absolute value of) the correlation between individual gene in a given module and the trait. The average GS across the module genes was used to characterize the correlation between modules and clinical traits. For each module, we also define a quantitative measure of module membership MM as the correlation of the module eigengene MEs (defined as the first principal component of a given module) and the gene expression profile. The relationships between MEs and clinical traits were analyzed, and the relevant modules were identified.

Functional and pathway enrichment analysis
------------------------------------------

We used the Database for Annotation Visualization and Integrated Discovery (DAVID) (<http://david.abcc.ncifcrf.gov/>) for gene functional annotation to determine biological functions. The genes in the significant histological type modules were uploaded in DAVID for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. We set a cutoff of adjusted *p* \< 0.05 for significant biological processes and significant pathways.

Survival analysis
-----------------

The prognosis profiles of the genes in significant histological type modules were analyzed using the R survival package from Bioconductor (<https://www.bioconductor.org>). Samples were classified as two subtypes based on gene expression. Samples with larger than median gene expression levels were defined as the "high expression" subtype; all other samples were defined as the "low expression" subtype. The log-rank *p*-value and survival visualization were performed using the R "survminer" package.

Results
=======

Metabolism-related DEGs in COAD
-------------------------------

We obtained gene expression TPM data from 289 COAD samples and 41 adjacent normal tissue samples, which included 60,498 genes. The QC analyzing result showed that the median and the quartile log 2 TPM value are similar between adjacent normal samples and cancer samples, indicating they are comparable ([Fig. S1](#supp-1){ref-type="supplementary-material"}). We used PCA to identify the possible outlier samples, and found that all the samples are located in the confidential ellipse ([Fig. 1A](#fig-1){ref-type="fig"}). We thus remained all of the samples to further analysis. To determine if metabolism-related genes influenced COAD, we first obtained 3,288 metabolism genes in RECON3, a most comprehensive human metabolic network model ([@ref-8]). We removed lowly expressed genes (TPM \<1) from the COAD and normal samples, and thus acquired 2,722 genes. We then determined DEGs in COAD compared with the normal tissue samples using ANOVA in R. We identified 2,114 DEGs with a cutoff of *p* \< 0.01 ([Fig. 1B](#fig-1){ref-type="fig"}), which included 1224 highly expressed genes and 890 lowly expressed genes ([Table S1](#supp-3){ref-type="supplementary-material"}). The profiles of the 2,114 DEGs are shown with heatmap in [Fig. 1C](#fig-1){ref-type="fig"}.

![The metabolism related DEGs in COAD.\
(A) The PCA was performed based on gene TPM of COAD and normal samples. (B) *X*-axis and *y*-axis of the Volcano plot represent gene expression fold-changes and negative logarithm to the base 10 of *p*-values, respectively. Red nodes indicate DEGs up regulated in COAD with *p*-value of \<0.01. Blue nodes indicate DEGs down regulated in COAD with *p*-value of \<0.01. (C) The heatmap of metabolism related DEGs in COAD. Each column represents a sample and each row represents one gene.](peerj-08-8421-g001){#fig-1}

Metabolism gene co-expression network constructed by WGCNA
----------------------------------------------------------

To explore the hub metabolism-related genes in COAD, we analyzed the co-expression network of the 2,114 DEGs using WGCNA. The power value is the most critical parameter that can affect the independence and average connectivity degree of co-expression modules. We screened network topology using different soft thresholding powers for later analysis ([Figs. 2A](#fig-2){ref-type="fig"}, [2B](#fig-2){ref-type="fig"}). The scale-free R2 equated to 0.90 at the power value of six. Therefore, the power value of six was used to construct the co-expression network with WGCNA, which was based on the hierarchical clustering of the calculated dissimilarities. The distance between clusters was defined as the average distance between all inter-cluster pairs. With a cutHeight of 0.25 ([Fig. 2C](#fig-2){ref-type="fig"}) and minimum gene number of 30, we merged the modules, with 12 then obtained ([Fig. 2D](#fig-2){ref-type="fig"}). We randomly selected 500 genes in the hierarchical clustering results, with the rows and columns representing each gene in each module. The deep red color indicated high topological overlap, suggesting that the co-expressed genes had similarity at the network topology level ([Fig. 2E](#fig-2){ref-type="fig"}, [Fig. S2](#supp-2){ref-type="supplementary-material"}).

![Twelve WGCNA modules of DEGs in COAD.\
(A--B) Soft-thresholding power analysis plot to fit the index of network topology. (C) Dendrogram of consensus module eigengenes from WGCNA analysis. The red line is the merging threshold, and groups of eigengenes below the threshold correlation need merged. (D) Hierarchical plot of co-expression clusters with corresponding color assignments. Each color represents a co-expression module by WGCNA. (E) Heatmap of the Topological Overlap Matrix (TOM) among 500 randomly selected genes from the DEG weighted co-expression network. Light and deep colors represent lower and higher overlap, respectively.](peerj-08-8421-g002){#fig-2}

Identifying genes in red module associated with histological typing
-------------------------------------------------------------------

To investigate the modules associated with clinical traits, we analyzed the module trait relationship. We first convert clinical trait data into variables which expressed in quantitative form, next we quantify gene relationship to clinical traits and important modules by using the gene significance and module membership (MM) measures. The results showed that the red module was significantly but negatively correlated with COAD clinical histological typing (*r* =  − 0.33, *p* = 4*e*−08) ([Fig. 3A](#fig-3){ref-type="fig"}). We also tested the relevance between each module and COAD clinical traits. The red module demonstrated much higher module significance than any other module, suggesting its stronger connection with COAD histological typing ([Fig. 3B](#fig-3){ref-type="fig"}), viz., non-mucin-producing colon adenocarcinoma (N-COAD) and mucin-producing colon adenocarcinoma (M-COAD). Red module membership was also significantly correlated with gene significance ([Fig. 3C](#fig-3){ref-type="fig"}). Taken together, our results indicated that the red module was significantly correlated to COAD histological typing.

![Correlation of Red module with clinical histological type.\
(A) Heatmap of model-trait relationship. Each cell include the the corresponding correlation and *p*-value. Each row and column corresponds to a module eigengene and a COAD clinical trait,respectively. The result indicated that the MEred module is highly correlated with the histological type with the *p*-value of 4e--8. COAD clinical traits(histology type: M-COAD,N-COAD; os_month:survival time(months); os_status:deceased or living; stage:AJCC_PATHOLOGIC_TUMOR_STAGE; M:AJCC_METASTASIS_PATHOLOGIC_PM; N:AJCC_NODES_PATHOLOGIC_PN; T: AJCC_TUMOR_PATHOLOGIC_PT\_). (B) Bar plot of gene significance across the WGCNA modules.The red module shows much higher GS than any other modules (C) Correlation between MEred membership and gene significance. (D) GO and (E) KEGG enrichment analysis of 199 genes in MEred. *Y*-axis is the significance of the enrichment results with the '--log10 (adjusted *p*-value)'.](peerj-08-8421-g003){#fig-3}

The red module contained 199 genes ([Table S2](#supp-2){ref-type="supplementary-material"}). To clarify the function of these genes, GO and KEGG pathway analyses were conducted using DAVID (v6.8). Genes in the red module were significantly enriched in ATP-binding (Benjamini--Hochberg method adjusted *p*-value = 4.83e−13) molecular function ([Fig. 3D](#fig-3){ref-type="fig"}) and in N-Glycan biosynthesis pathways (Benjamini--Hochberg method adjusted *p*-value = 6.23e−04) ([Fig. 3E](#fig-3){ref-type="fig"}).

Significant association of GDE1 gene with histological typing and prognosis
---------------------------------------------------------------------------

To identify which genes in the red module were associated with different histological typing and prognosis of COAD, we performed survival analysis ([Table 1](#table-1){ref-type="table"}). We found GDE1 to be the most significant prognosis-related gene. This gene demonstrated lower expression in COAD at the RNA level ([Fig. 4A](#fig-4){ref-type="fig"}) and its expression level was significantly associated with survival time (*p* = 0.001; [Table 1](#table-1){ref-type="table"}). Interestingly, we also observed that GDE1 expression in N-COAD was significantly lower than that in normal tissues (*p* \< 1e−6) but higher than that in M-COAD (*p* = 0.003) ([Fig. 4A](#fig-4){ref-type="fig"}). Furthermore, GDE1 was the most significant gene correlated with N-COAD subtype prognosis ([Table 1](#table-1){ref-type="table"}).

10.7717/peerj.8421/table-1

###### Top 10 significant prognosis in different histological type of COAD.

![](peerj-08-8421-g005)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene       Gene\                                       All COAD\                                       N-COAD\                                         M-COAD\
             expression\                                 prognosis\                                      prognosis\                                      prognosis\
             direction                                   HR (*p*-value)                                  HR (*p*-value)                                  HR (*p*-value)
  ---------- ------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------
  GDE1       Down[^\*\*\*^](#table-1fn){ref-type="fn"}   0.41(0.001[^\*\*^](#table-1fn){ref-type="fn"}   0.4(0.0017[^\*\*^](#table-1fn){ref-type="fn"}   0.93(0.92)

  DARS       Up[^\*\*\*^](#table-1fn){ref-type="fn"}     2.1(0.0043[^\*\*^](#table-1fn){ref-type="fn"}   2(0.0091[^\*\*^](#table-1fn){ref-type="fn"}     2.9(0.1)

  SLCO4A1    Up[^\*\*\*^](#table-1fn){ref-type="fn"}     2(0.0066[^\*\*^](#table-1fn){ref-type="fn"}     1.7(0.043[^\*^](#table-1fn){ref-type="fn"}      3.1(0.087)

  EPHB2      Up[^\*\*\*^](#table-1fn){ref-type="fn"}     0.53(0.016[^\*^](#table-1fn){ref-type="fn"}     0.51(0.019[^\*^](#table-1fn){ref-type="fn"}     0.97(0.96)

  B3GNT8     Down[^\*\*\*^](#table-1fn){ref-type="fn"}   0.54(0.02[^\*^](#table-1fn){ref-type="fn"}      0.53(0.022[^\*^](#table-1fn){ref-type="fn"}     0.68(0.56)

  DGUOK      Up[^\*\*\*^](#table-1fn){ref-type="fn"}     1.7(0.029[^\*^](#table-1fn){ref-type="fn"}      1.7(0.052)                                      2.3(0.2)

  MARS2      Up[^\*\*\*^](#table-1fn){ref-type="fn"}     0.57(0.03[^\*^](#table-1fn){ref-type="fn"}      0.67(0.15)                                      1.1(0.92)

  MAPKAPK5   Up[^\*\*\*^](#table-1fn){ref-type="fn"}     0.57(0.031[^\*^](#table-1fn){ref-type="fn"}     0.58(0.053)                                     0.35(0.099)

  AURKA      Up[^\*\*\*^](#table-1fn){ref-type="fn"}     0.59(0.041[^\*^](#table-1fn){ref-type="fn"}     0.7(0.2)                                        1(0.98)

  ALG1       Up[^\*\*\*^](#table-1fn){ref-type="fn"}     0.6(0.054)                                      0.75(0.3)                                       0.57(0.36)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes.**

HR represents the Hazard ratio.

Significances are cataloged as ^∗^*P* -value of 0.05--0.01, ^∗∗^*P*-value of 0.01 − 10^−6^, or ^∗∗∗^*P* \< 10^−6^.

This table was ranked by the *p*-value of the prognosis of all COAD samples.

![Survival profile of GDE1 in different histological typing of COAD.\
(A) Gene expression profile of GDE1 in normal (*n* = 41), M-COAD (*n* = 38), and N-COAD (*n* = 233). (B) Survival curve in M-COAD (*n* = 38) and N-COAD (*n* = 233). (C) Survival curves of N-COAD with high (magenta, *n* = 116) and low (dark cyan, *n* = 117) GED1 expression. (D) Survival curves of M-COAD with high (magenta, *n* = 19) and low (dark cyan, *n* = 19) GED1 expression.](peerj-08-8421-g004){#fig-4}

Although different histological subtypes of COAD showed similar prognosis profiles ([Fig. 4B](#fig-4){ref-type="fig"}), we found that the correlation of GDE1 with prognosis was distinct in the N-COAD and M-COAD subtypes ([Figs. 4C](#fig-4){ref-type="fig"} and [4D](#fig-4){ref-type="fig"}). Specifically, GDE1 was significantly associated with N-COAD prognosis (*p* = 0.0017), and N-COAD with high GDE1 expression demonstrated significantly longer survival time ([Fig. 4C](#fig-4){ref-type="fig"}). In M-COAD, however, GDE1 was not correlated with prognosis (*p* = 0.92) ([Fig. 4D](#fig-4){ref-type="fig"}). Taken together, our results showed that GDE1 was specially associated with N-COAD subtype prognosis, suggesting that it could be a potential novel cancer target for N-COAD.

Discussion
==========

Both the incidence and mortality of COAD have increased markedly in colorectal cancer in the past few decades ([@ref-11]). From a molecular basis, COAD results from multistep processes of aberration and accumulation, which drive malignant transformation of normal colon cells ([@ref-18]). However, the genetic changes responsible for the development and progression of COAD are still under investigation.

In this study, we obtained 2,114 metabolism-related DEGs in COAD, among which we identified GDE1 as the most significant gene related to prognosis and histological typing of COAD. This gene (also referred to as MIR16 or 363E6.2), localized on chromosome 16 (16p12.3) and containing six exons and five introns (<https://www.ncbi.nlm.nih.gov>), produces a 331-residue protein with an apparent molecular mass of 37.7 kDa ([@ref-3]). The expression of GDE1 in mammalian tissues was first identified in 2000 ([@ref-31]). It is an integral membrane glycoprotein and interacts with the RGS16 proteins, which regulates G protein signaling.

GDE1 also participates in glycerophosphoinositol-phosphodiesterase (GPI-PDE) activity. GDE1 possesses the evolutionarily conserved GDE domain. The GDE domain contains a putative catalytic motif ([@ref-30]), which is important for GDE1-mediated hydrolysis of glycerophosphoinositol (GPI) ([@ref-30]). GDE1 prefers GPI and some of its phosphorylated derivatives as potential substrates and demonstrates dramatic GPI-PDE activity ([@ref-30]). As a GPI-PDE, GDE1 can further hydrolyze GPI to its final catabolic products, inositol and glycerol 3-phosphate ([@ref-30]). Interestingly, inositol has been proven to show moderate anticancer activity in cell proliferation and differentiation ([@ref-4]), and thus prevents the formation and incidence of several cancers alone or in combination with IP6, such as colon, breast, and lung cancer ([@ref-4]; [@ref-27]; [@ref-5]; [@ref-28]). Inositol is considered to be the parent compound of IP6 when all of its six carbons are attached to phosphate groups, and IP6 can be converted to inositol by removing all six phosphates ([@ref-28]). In addition, inositol is a precursor in the phosphatidylinositol cycle and conducts important second messengers in cellular signal transduction systems, such as phosphatidylinositol 4,5-bisphosphate (PIP2) and inositol 1,4,5-P3(IP3). Taken together, these studies show that inositol, as an enzymatic product of GDE1, plays a key role in anti-cancer.

Contra to the attention paid to the anti-cancer effects of inositol, little is known about the connection between GDE1 and cancer. In this study, we provide the first piece of evidence to show that GDE1 is an important tumor suppressor gene through the function of its metabolite inositol. Indeed, GDE1 demonstrated significantly lower expression in COAD tissues compared with normal tissues. Furthermore, its expression level showed a positive correlation with survival time; i.e., COAD patients with lower GDE1 expression displayed a shorter survival time. A possible explanation for this observation is that lower expression of GDE1 converted to less inositol, with less inositol resulting in poorer prognosis. Previous studies have indicated that increasing concentrations of inositol *in vivo* and *in vitro* may control cancer metastases and improve quality of life ([@ref-4]; [@ref-27]; [@ref-28]; [@ref-16]; [@ref-1]; [@ref-24]; [@ref-9]; [@ref-10]; [@ref-21]). Supporting evidence for this comes from our survival analysis results, in which higher expression of GDE1 showed better survival in COAD.

Furthermore, GDE1 showed different expression levels in different histological subtypes of COAD. Variant histological subtypes are reportedly associated with different survival outcomes ([@ref-13]) and treatments. For example, chemotherapy and radiotherapy have been administered to a higher percentage of patients with mucinous tumors than patients with non-mucinous adenocarcinomas ([@ref-13]). Individual therapy for different histological subtypes may result in an optimal effect. In our study, the expression of GDE1 in N-COAD was higher than that in M-COAD. In addition, N-COAD showed better survival with higher expression of GDE1. In contrast, there was no correlation between GDE1 and prognosis in M-COAD. Therefore, GDE1 may serve as a prognostic factor and candidate target in the N-COAD subtype.

Conclusions
===========

Our results suggest that GDE1 may be a cancer suppressor by up-regulating the inositol metabolism pathway. Its high association with N-COAD prognosis suggests this gene could also act as a promising cancer therapeutic target for this COAD subtype.
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###### The correlation network of the up and downregulated genes in red module using cytoscape networking

Magenta are the upregulated genes in red module. Blue are the down regulated genes in red module.
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